Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

[p15(INK4B) methylation on prognosis and response to decitabine in patients with MDS].

Authors: Zhang, Yao  Song, Lu-xi  Wu, Ling-yun  Chang, Chun-kang  Li, Xiao 
Citation: Zhang Y, etal., Zhonghua Xue Ye Xue Za Zhi. 2013 Mar;34(3):237-41. doi: 10.3760/cma.j.issn.0253-2727.2013.03.013.
Pubmed: (View Article at PubMed) PMID:23683424
DOI: Full-text: DOI:10.3760/cma.j.issn.0253-2727.2013.03.013

OBJECTIVE: To detect p15(INK4B) methylation levels and the kinetics of the methylation status before and after decitabine to explore its influences on prognosis and response to decitabine in myelodysplastic syndromes (MDS) patients.
METHODS: We examined 261 MDS patients (143 male and 118 female) with the median age of 52 years (32-78). Of them, 172 cases were low-risk group (low-risk 104 cases, intermediate-1 68 cases), 89 cases high-risk group (intermediate-2 52 cases, high risk 37 cases). Collections of bone marrow mononuclear cells of MDS patients and extracted the genomic DNA, the methylation status of p15(INK4B) was detected by methylation-specific PCR (MSP) method. Survival analysis was conducted according to the level of p15(INK4B) methylation in the cohort of patients. The kinetics of the methylation levels of p15(INK4B) in 58 MDS patients before and after 2 courses of decitabine have been assessed with the method of MSP.
RESULTS: The methylation level of p15(INK4B) in low-risk group patients was significantly lower than that in high-risk group (117.22 vs 157.63, P<0.05 ). The expected 2-year survival rate of p15(INK4B) methylation positive patients was lower than that of negative ones (91.8% vs 69.8%, P<0.05); the expected 2-year survival rate of p15(INK4B) methylation positive patients was shorter than that of negative ones in low-risk group(78.2% vs 92.0%, P<0.05), meanwhile there was no significant difference in terms of expected 2-year survival rate and median expected survival between p15(INK4B) methylation positive and negative patients in high-risk group [35.6% vs 38.5%, (17.0±9.3) month vs (18.0±5.7) month, P>0.05]. Multivariate analysis showed p15(INK4B) methylation degree was an independent prognostic factor for overall survival. No statistical difference of overall response (OR) rates were found between p15(INK4B) methylation positive patients and negative patients before decitabine(65.9% vs 76.5%, P>0.05), and complete remission (CR) rates between these two groups also showed no statistical difference(22.0% vs 29.4%, P>0.05). p15(INK4B) methylation levels had no obvious change before and after treatment in decitabine responders(P>0.05).
CONCLUSION: The survival of newly diagnosed MDS patients with positive p15(INK4B) methylation was comparatively shorter, but p15(INK4B) methylation had no influence on response to decitabine.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11252195
Created: 2016-06-28
Species: All species
Last Modified: 2017-01-03
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.